Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Sloan-Kettering Institute for Cancer Research

Sunesis Pharmaceuticals, Inc.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Merck Sharp & Dohme LLC

Msd Italia S.r.l.

Msd R&d Co., Ltd.

Shawn J Stachel

Jian Li

Craig Alan Coburn

Joseph P Vacca

Harold G Selnick

Philippe G Nantermet

Daniel Vincent Paone

Michael T Rudd

Shimin Xu

Anthony T Ginnetti

Hemaka Anthony Rajapakse

Edward J Brnardic

Ian M Bell

Shaun R Stauffer

James J Perkins

Jian Liu

Mark E Layton

Michael J Breslin

Christopher James Bungard

Thomas G Steele

Zhe Wu

Nigel J Liverton

Yongxin Han

Michael P Dwyer

Ashok Arasappan

James C Barrow

Hong Liu

Harry R Chobanian

Jianmin Fu

Paul Tempest

Zhaoyang Meng

Christopher Joseph Sinz

Jing Li

Deodial Guy Guiadeen

David Jonathan Bennett

Keith P Moore

Jiuxiang Zhu

Yili Chen

Jenny Wai

Kristen L G Jones

Linda M Suen-Lai

Xuewang Xu

Samuel J Danishefsky

John M Sanders

Yimin Qian

Matthew G Stanton

Hao Wu

Samuel L Graham

Melissa S Egbertson

Dong-Ming Shen

Craig A Stump

Michael R Wood

Deping Wang

Jason M Cox

Christopher S Burgey

Richard Berger

Bin Zhu

Georgia B McGaughey

Ashley Forster

Darrell Henze

Linghang Zhuang

Yuntae Kim

Kun Liu

Stephane L Bogen

Robert S Meissner

Wenjin Yang

C Blair Zartman

Robert M Garbaccio

Peter J Manley

Richard Soll

Alessia Petrocchi

M Katharine Holloway

Dane James Clausen

Donnette D Staas

William D Shipe

Neal Rosen

Kausik K Nanda

Dexi Yang

Daniel Baeschlin

Barbara Hanney

Melody McWherter

Vanessa L Rada

Jennifer R Davis

June J Kim

Mark Donald Chappell

Jonathan E Wilson

Zhigang Guo

Michael David VanHeyst

Jeffrey W Schubert

Wanli Lu

Bruce Fahr

John Jin Lim

Xiaoxing Du

Yaxian Cai

Ivory D Hills

Yingjian Bo

Haitang Li

Kristen G Jones

David Solit

Hong Zhu

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors

2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors

The present invention is directed to pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Pyrrolidine orexin receptor agonists

2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors

In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R, R, R, L, R, L, Q, and Rare as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-&#x3b2; receptor (LXR&#x3b2;) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease. 

Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders. 

2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors

In its many embodiments, the present invention provides certain substituted N-aryl and N-heteroaryl piperidine compounds of the Formula (I): 

N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use

In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R, R, R, L, R, L, Q, and Rare as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-&#x3b2; receptor (LXR&#x3b2;) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease. 

Piperidine derivatives as liver X receptor beta agonists, compositions, and their use

The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (I) and (II) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Bicyclic heterocyclic compounds as PDE2 inhibitors

In its many embodiments, the present invention provides substituted cyanopyridine containing compounds of the Formula (I): and acceptable salts thereof, wherein R, R, R, R, R, X, Y, Q, and the moiety are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-&#x3b2; receptor (LXR&#x3b2;) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease. 

Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use

The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction. 

6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Cathepsin cysteine protease inhibitors

The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved. 

Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease

Growing community of inventors

Perkasie, PA, United States of America

Shawn J Stachel